Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8697689B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 15, 2009 |
| Grant date | Apr 15, 2014 |
| Priority date | — |
| Expiry date | Oct 15, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel compounds, in particular novel indole and benzomorpholine derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions as well as to the use of such compounds or compositions for the prevention and treatment of such diseases in which mGluR2 is involved.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.